The authors appreciate the comments by Drs. Gatti and Bertazzoli concerning our case report on fatal hepatotoxicity secondary to the non-steroidal antiinflammatory drug (NSAID) nimesulide. We have taken up the criticism that our method for calculating the odds ratio for hepatic adverse effects is not applicable since nimesulide and COX-2 selective NSAIDs confer a smaller risk of gastrointestinal side effects, thus rendering the denominator of our odds ratio calculation too variable. We have repeated the odds ratio analysis on unsolicited reports of drug-related side effects registered in the World Health Organization database (online search kindly performed by R. Stoller from the Pharmacovigilance Centre of the ''Interkantonale Kontrollstelle fu¨r Heilmittel'' IKS, Bern, Switzerland). To test the hypothesis of Drs. Gatti and Bertazzoli, we have compared the proportion of hepatic side effects in relation to (i) the total number of reported side effects and (ii) the total number of reported side effects excluding gastrointestinal side effects. As shown in Table 1 , exclusion of adverse reports related to the gastrointestinal tract does not change the odds ratio estimate, thereby invalidating this concern. In contrast to nimesulide, which clearly shows the highest odds ratio for hepatic adverse effects of all NSAIDs (Table 1) , the odds ratio of the coxib celecoxib is only 0.8 (95% confidence interval 0.6, 1.0) in comparison with ibuprofen.
The second comment of Drs. Gatti and Bertazzoli questions our assumption that the total number of reports approximately reflects the relative prescription frequencies, since not all NSAIDs exhibit similar frequencies in causing hepatic and gastrointestinal ADRs. We entirely agree that calculation of an absolute risk is undoubtedly the best measure of the importance of a drug-side effect association, since it indicates how commonly an ADR is likely to occur in a group of exposed individuals. However, for the calculation of absolute risks it is essential that the primary data sources for the drugs in question are comparable. In the absence of rigorously controlled randomised trials or of comprehensive pharmacoepidemiological databases, the likelihood of confounding biases that compromise the validity of the results is no less than in the observational approach adopted by us. For nimesulide, the absolute risk is calculated from the number of spontaneous reports divided by the sales figures. However, underreporting is a wellestablished serious problem for spontaneous report systems [1, 2] . Because nimesulide is mainly marketed in countries with a low frequency of ADR reporting in relation to population size, the problem of underreporting is further aggravated. We would like to emphasise that the relative risk or odds ratio is the most frequently reported epidemiological parameter and is well suited for establishing an association between a drug and an ADR in the context of an established causality.
The third concern relates to the increased reporting rate secondary to the sharpened awareness of and sensitisation to a particular side effect of a drug. As shown in Table 2 , it is of note that the odds ratio for nimesulide was already significantly elevated (9.6 in comparison with ibuprofen in 1996/1997) before the first report of nimesulide-induced acute liver injury was published in 1998. This excludes the possibility of a reporting bias secondary to publications in the literature and is a further indication that nimesulide indeed causes hepatic ADRs more frequently than other NSAIDs. 
